Oncologic Drugs Advisory Committee (ODAC) has recognized a favorable benefit risk profile for AstraZeneca's TRUQAP® (capivasertib) in combination with abiraterone and androgen deprivation therapy (ADT ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results